Exvastat has developed Impentri™, the first stable intravenous formulation of imatinib, designed to inhibit vascular leak in patients suffering from Acute Respiratory Distress Syndrome (ARDS). This treatment addresses the critical lack of approved pharmacotherapy for ARDS, which results in high mortality rates and significant healthcare costs.
Funding
$3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute Respiratory Distress Syndrome (ARDS) is a severe condition characterized by widespread lung inflammation and fluid accumulation, leading to high mortality rates. Currently, there are no approved pharmacological treatments for ARDS, leaving supportive ventilatory care as the primary option.
Solution
Exvastat has developed Impentri™, an intravenous formulation of imatinib designed to inhibit vascular leak in ARDS patients. Impentri™ addresses the unmet need for a direct ARDS therapy by targeting the vascular permeability that drives pulmonary edema. The intravenous delivery method allows for rapid administration in critical care settings, even when patients are unable to take oral medications due to coma or mechanical ventilation. By reducing vascular leak, Impentri™ aims to decrease mortality and morbidity associated with ARDS, potentially lowering the overall cost of care. Clinical data, including human case reports and in vivo models, suggest that Impentri™ can be effective in treating ARDS by addressing the underlying mechanism of vascular leak.
Target Audience
The primary target audience includes critical care physicians and hospital systems treating patients with Acute Respiratory Distress Syndrome (ARDS).
Features
- Intravenous formulation of imatinib for direct administration in critical care.
- Designed to inhibit vascular leak, reducing pulmonary edema in ARDS patients.
- Suitable for patients unable to receive oral treatments due to coma or mechanical ventilation.
- Demonstrated efficacy in human case reports and in vivo models.